title: Canagliflozin versus placebo for post-bariatric surgery patients with persistent type II diabetes: A randomized controlled trial (CARAT).
authors.affiliation: Department of Endocrinology and Metabolism, Cleveland Clinic, Cleveland, Ohio.
authors.forename: Karim
authors.identifier: 0000-0003-4549-1512
authors.initials: K
authors.lastname: Kheniser
authors.affiliation: Department of Endocrinology and Metabolism, Cleveland Clinic, Cleveland, Ohio.
authors.forename: Sangeeta R
authors.initials: SR
authors.lastname: Kashyap
mesh_terms: D000328:Adult; D000368:Aged; D050110:Bariatric Surgery; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D000068896:Canagliflozin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000601:surgery*; D005260:Female; D006442:Glycated Hemoglobin / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011184:Postoperative Period; D017211:Treatment Failure; D055815:Young Adult
chemical_list: D001786:Blood Glucose; D000068896:Canagliflozin; D006442:Glycated Hemoglobin; D010919:Placebos; C517652:hemoglobin A1c protein, human